Respiratory infections multiplex, nucleic acid detection (including SARS-CoV-2)

Scheme information

Service

EQAS

Scheme

Respiratory infections multiplex, nucleic acid detection

Service provider

Labquality

Accreditation

Not accredited

Status

New scheme in 2018

Target

Laboratories

Coverage

Analytical phase

Rounds

4

Distributions

Europe, the Middle East and Asia

Coordinator

Jaana Paakkanen

Expert

Matti Waris

Products

5300 / Respiratory infections multiplex, nucleic acid detection

Samples: 4 simulated samples, ≥ 0.5mL each

Type: Physical

Examinations: Direct multiplex nucleic acid detection. Pathogens included are Adenovirus, B. parapertussis, B. pertussis, C. pneumoniae, Coronavirus (OC43, 229E, NL63, HKU1), Enterovirus, Influenzavirus A/B, Metapneumovirus, M. pneumoniae, Parainfluenzavirus 1-4 , Rhinovirus, RSV A/B, SARS-CoV-2, S. pneumoniae

Additional information: Pathogens are covered during annual scheme: participation to all rounds required

Search other products Show similar products

Pin It on Pinterest

Share This